Sarepta Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Monday, from 92 to 99.
The new score means the company is now outperforming 99% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Sarepta Therapeutics has now climbed above a proper buy zone after clearing the 146.68 buy point in a consolidation.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock sports an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 81% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
The company posted a 0% rise in earnings for Q1. Sales growth climbed 63%, up from 54% in the prior report. The company has now posted rising growth in each of the last three reports.
Sarepta Therapeutics earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the top-ranked stock within the group.
